EZH2基因的突变与骨髓肿瘤患者的不良预后相关。

Zhang Qi, Han Qi, Zi Jie, Ma Jinlong, Song Huihui, Tian Yulu, McGrath Mary, Song Chunhua, Ge Zheng

Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.

Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

Genes Dis. 2019 May 16;6(3):276-281. doi: 10.1016/j.gendis.2019.05.001. eCollection 2019 Sep.

EZH2 is a component of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. EZH2 mutations are associated with oncogenesis and progression of cancers. However, the relationship between the clinical outcome of patients with myeloid malignancies and EZH2 mutations is controversial. Therefore, we performed a meta-analysis of 8 studies (n = 2243 patients) that evaluates the correlation between EZH2 mutations and overall survival (OS) in patients with myeloid neoplasms. EZH2 mutations were associated with significantly worse OS (hazard ratio [HR] = 2.37, 95% confidential interval (CI), 1.48-3.79). In a word, EZH2 mutations indicate a poor prognosis for patients with myeloid neoplasms.

EZH2是多梳抑制复合物2（PRC2）的一个组成部分，PRC2是一种高度保守的组蛋白甲基转移酶，可使组蛋白3的赖氨酸27发生甲基化。EZH2突变与癌症的发生和进展相关。然而，髓系恶性肿瘤患者的临床结局与EZH2突变之间的关系存在争议。因此，我们对8项研究（n = 2243例患者）进行了荟萃分析，以评估EZH2突变与髓系肿瘤患者总生存期（OS）之间的相关性。EZH2突变与显著更差的OS相关（风险比[HR]=2.37，95%置信区间[CI]，1.48 - 3.79）。总之，EZH2突变表明髓系肿瘤患者预后不良。